Trial Profile
A trial to study the effect of nivolumab in patients with lung squamous cell carcinoma, and to study C-reactive protein (CRP) as a predictive marker for immunotherapy in lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Aug 2016
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Lung cancer; Squamous cell cancer
- Focus Pharmacodynamics
- 04 Aug 2016 New trial record
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology